The CSF p-tau level in patients with ALS and cognitive impairment (5.78 ± 0.48 pg/mL, n = 18) was higher than that of patients without cognitive impairment (3.17 ± 0.30 pg/mL, n = 30; P < 0.0001). Here, MAPT is linked to Cognitive impairment.